| Phenotypic Profile |
| Category |
Entity |
Quantity |
Experimental Paradigm |
Age at Testing |
| Circadian sleep/wake cycle |
Sleep pattern1 |
No adverse effect
Description: Isoguvacine did not cause sedation in mice.
Exp Paradigm: NA
|
General observations |
6 weeks |
| |
|
Description: Isoguvacine did not cause sedation in mice.
Exp Paradigm: NA |
|
|
| Sensory |
Sensorimotor gating: tactile cue1 |
Restored
Description: Isoguvacine decreased percent prepulse inhibition of the startle response to a 125 db noise, when the startle noise is preceded by a light air puff, in mutants.
Exp Paradigm: NA
|
Prepulse inhibition |
6 weeks |
| |
|
Description: Isoguvacine decreased percent prepulse inhibition of the startle response to a 125 db noise, when the startle noise is preceded by a light air puff, in mutants.
Exp Paradigm: NA |
|
|
| Sensory |
Startle response: acoustic stimulus1 |
No adverse effect
Description: Isoguvacine treatment did not change startle response amplitude to 125db noise.
Exp Paradigm: NA
|
Acoustic startle reflex test |
6 weeks |
| |
|
Description: Isoguvacine treatment did not change startle response amplitude to 125db noise.
Exp Paradigm: NA |
|
|
| Sensory |
Sensorimotor gating: tactile cue1 |
Restored
Description: Isoguvacine treatment decreased response to air puff alone in mutants.
Exp Paradigm: NA
|
Response to air puff |
6 weeks |
| |
|
Description: Isoguvacine treatment decreased response to air puff alone in mutants.
Exp Paradigm: NA |
|
|
|
| Not Reported: |
Communications, Developmental profile, Emotion, Immune response, Learning & memory, Maternal behavior, Molecular profile, Motor phenotype, Neuroanatomy / ultrastructure / cytoarchitecture, Neurophysiology, Physiological parameters, Repetitive behavior, Seizure, Social behavior, |
